About

I am pleased to be part of such a dedicated team, with extensive combined experience of developing biological products through to approval and commercialisation. We are focussed on the continued development of emactuzumab as a potentially best-in-class treatment for patients with TGCT and other macrophage-driven pathologies around the globe. This is a critical and exciting stage of the company's journey and we all look forward to pursuing our mission.

Ray Barlow

Chief Executive Officer

Our mission

At SynOx, we understand the power of being in control of your own journey in the treatment of your disease.

Our mission is to establish emactuzumab as a best-in-class drug of choice to address the unmet needs, and improve the quality of life, of as many patients as possible.

By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.

SynOx Therapeutics was established in November 2020 following the licensing from Roche of the exclusive worldwide rights to emactuzumab, a potentially best-in-class CSF-1R monoclonal antibody. Emactuzumab has a well-tolerated safety profile and has shown promising efficacy in patients suffering from TGCT, a rare and debilitating disease that causes significant pain and disability.

SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation. It is backed by a strong syndicate of premier life sciences investors.

Our team

  • Ray Barlow

    Chief Executive Officer
    X

    Ray Barlow

    Chief Executive Officer

    Ray was appointed as CEO of SynOx Therapeutics in May 2021. Ray has over 20 years’ experience of the biopharmaceutical industry gained through leadership positions in scientific, clinical, commercial, and executive roles. Ray has diverse experience gained in global pharmaceutical companies (AstraZeneca, J&J and Amgen), publicly listed biotechs (Emergent BioSolutions Inc, Crucell N.V., e-Therapeutics PLC and Kiadis N.V.) and private companies such as Asterion Limited.

    Ray has very strong corporate development experience, right across the value chain and has led and closed numerous M&A, licensing, commercial, manufacturing, equity-based and IP-based deals collectively worth multiple billions of dollars. Prior to his industrial career, Ray completed a PhD at Manchester University, UK and did postdoctoral research at McGill University, Canada.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Hamina Patel

    Chief Medical Officer
    X

    Hamina Patel

    Chief Medical Officer

    Hamina was appointed Chief Medical Officer of SynOx in May 2023. Hamina is a pharmaceutical executive with more than 20 years’ industry experience, leading global cross functional teams in the development and commercialisation of drugs primarily within the field of oncology. Hamina was previously Director of Drug Development, Oncology, at Johnson and Johnson, where she helped to build a broad and differentiated portfolio of indications for the cancer drug VELCADE® and was instrumental in the success of a new indication (the second-line treatment of mantle cell lymphoma) based on a Phase II clinical study in more than 35 countries. She received numerous awards for her contribution to the Oncology group at Johnson and Johnson, including a Standard of Leadership award. Hamina qualified as a physician in 1990 and worked for almost ten years in hospitals around the UK before moving into the pharmaceutical industry.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Broes Naeye

    Chief Technology Officer
    X

    Broes Naeye

    Chief Technology Officer

    Broes joined SynOx Therapeutics in June 2021 with more than 10 years of experience in development and commercialisation of biopharmaceuticals. Most recently, he served as Global Product Supply Lead at Sanofi, where he was responsible for the global supply of Dupixent®. Previously, he worked as Head of Commercial Supply and CMC Project Lead at Ablynx. Broes graduated as a pharmacist and holds a PhD in biochemistry from the University of Ghent, Belgium.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Sarah Clare

    SVP, Finance and Operations
    X

    Sarah Clare

    SVP, Finance and Operations

    Sarah joined SynOx Therapeutics in July 2021. She is a Chartered Accountant with over 10 years’ experience in finance. She trained at Blick Rothenberg in London and has since gained experience across a wide range of management, operations and compliance. She was responsible for technical financial reporting at a large multinational group before more recently focussing on life sciences, taking on more responsibility across the finance, admin and corporate governance frameworks in an AIM-listed environment. Sarah also attended Imperial College London where she attained a first class BSc (Hons) in Biology and Business Management.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Sander Veltkamp

    VP, External Affairs and Business Development
    X

    Sander Veltkamp

    VP, External Affairs and Business Development

    Sander joined SynOx Therapeutics in January 2022, bringing over 15 years of early and late phase clinical development, medical and regulatory experience at (bio)pharmaceutical companies. Sander has played a key role in the successful launch of innovative targeted medicine in oncology, haematology and other therapeutic areas for patients with severe and rare diseases.

    Sander gained experience in international (bio)pharmaceutical companies (Astellas, Takeda, Abbvie and Gilead) where he fulfilled strategic, operational and leadership positions and was responsible for driving the global development and commercialisation of novel personalised medicine in Europe, US and Japan.

    Sander graduated as a pharmacist and holds a registration as Clinical Pharmacologist from the University of Utrecht and completed his PhD in Medical Oncology and Clinical Pharmacology at the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

Board of Directors

  • Ton Logtenberg

    Non-Executive Chairman
    X

    Ton Logtenberg

    Non-Executive Chairman

    Ton joined SynOx Therapeutics in May 2021 as Non-Executive Director and Chairman of the Board of Directors. Ton has over 25 years’ experience in the biopharmaceutical industry as a co-founder and Chief Scientific Officer of Crucell N.V. and founder, President and CEO of Merus N.V.

    Ton has extensive experience in founding biotech companies and taking them from start-up to public listings on the Nasdaq and Euronext exchanges and beyond. Ton completed a PhD in Immunology at Utrecht University, the Netherlands and undertook postdoctoral research at Columbia University in New York. Ton has held a professorship in Immuno-biotechnology at Utrecht University and is currently a professor in Entrepreneurship in the Life Sciences at the same University.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Ray Barlow

    Chief Executive Officer
    X

    Ray Barlow

    Chief Executive Officer

    Ray was appointed as CEO of SynOx Therapeutics in May 2021. Ray has over 20 years’ experience of the biopharmaceutical industry gained through leadership positions in scientific, clinical, commercial, and executive roles. Ray has diverse experience gained in global pharmaceutical companies (AstraZeneca, J&J and Amgen), publicly listed biotechs (Emergent BioSolutions Inc, Crucell N.V., e-Therapeutics PLC and Kiadis N.V.) and private companies such as Asterion Limited.

    Ray has very strong corporate development experience, right across the value chain and has led and closed numerous M&A, licensing, commercial, manufacturing, equity-based and IP-based deals collectively worth multiple billions of dollars. Prior to his industrial career, Ray completed a PhD at Manchester University, UK and did postdoctoral research at McGill University, Canada.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Ton Logtenberg

    Non-Executive Chairman
    X

    Ton Logtenberg

    Non-Executive Chairman

    Ton joined SynOx Therapeutics in May 2021 as Non-Executive Director and Chairman of the Board of Directors. Ton has over 25 years’ experience in the biopharmaceutical industry as a co-founder and Chief Scientific Officer of Crucell N.V. and founder, President and CEO of Merus N.V.

    Ton has extensive experience in founding biotech companies and taking them from start-up to public listings on the Nasdaq and Euronext exchanges and beyond. Ton completed a PhD in Immunology at Utrecht University, the Netherlands and undertook postdoctoral research at Columbia University in New York. Ton has held a professorship in Immuno-biotechnology at Utrecht University and is currently a professor in Entrepreneurship in the Life Sciences at the same University.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Ray Barlow

    Chief Executive Officer
    X

    Ray Barlow

    Chief Executive Officer

    Ray was appointed as CEO of SynOx Therapeutics in May 2021. Ray has over 20 years’ experience of the biopharmaceutical industry gained through leadership positions in scientific, clinical, commercial, and executive roles. Ray has diverse experience gained in global pharmaceutical companies (AstraZeneca, J&J and Amgen), publicly listed biotechs (Emergent BioSolutions Inc, Crucell N.V., e-Therapeutics PLC and Kiadis N.V.) and private companies such as Asterion Limited.

    Ray has very strong corporate development experience, right across the value chain and has led and closed numerous M&A, licensing, commercial, manufacturing, equity-based and IP-based deals collectively worth multiple billions of dollars. Prior to his industrial career, Ray completed a PhD at Manchester University, UK and did postdoctoral research at McGill University, Canada.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Carl Kilander
    X

    Carl Kilander

    Carl Kilander is a partner of HealthCap. Prior to joining HealthCap in 2019, Carl co-founded and was CEO of a health- tech start-up exited in 2019. Carl is a Medical Doctor trained at the Karolinska Institute and at Harvard Medical School. Carl worked clinically in general surgery and pursued research in the field of hepato-biliary malignancies at the Karolinska Institute rendering him a PhD in clinical epidemiology in 2017. He is the author of 5 scientific papers published in peer-reviewed journals. Carl represents HealthCap as a director on the board of SynOx Therapeutics and is an observer on the board of Aro Biotechnologies, Pretzel Therapeutics and Doctrin.

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • Dirl Kersten
    X

    Dirl Kersten

    Dirk is a General Partner at Forbion and manages the Forbion Growth Opportunities Fund. Dirk is a physicist by training and previously worked as a Partner at Gilde Healthcare Partners, where he led their Boston/US operations. Furthermore, Dirk was a Managing Director at INKEF Capital responsible for all life sciences investment activities. Dirk led a series of investments in Europe and the US, including: Dyne Therapeutics (NASDAQ: DYN) Ascendis Pharma (NASDAQ: ASND), Profibrix (acquired by MEDCO), Lanthio Pharma (acquired by Morphosys), Nightbalance (acquired by Philips), Audion Therapeutics (private).

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • X

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • X

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

  • X

    synox

    SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

    © SynOx Therapeutics.
    Last Revised: July 2022.

Our investors